Congratulations to MedSci Healthcare Successfully Listing on the Hong Kong Stock Exchange | 5Y News

On December 23, 2022, MedSci Healthcare Holdings Limited (hereinafter referred to as "MedSci" or the "Company"; stock code: 0314.HK) was listed on the Main Board of the Hong Kong Stock Exchange.

Mr. Ma Xuguang, Executive Director, Chairman of the Board, and Chief Executive Officer of MedSci, said: "Today, we are delighted that the Company has been listed on the Hong Kong Stock Exchange. This marks an important milestone and a new beginning for MedSci's development. We are also deeply grateful to all our investors for their support throughout the Company's journey.

Since our founding in 2014, we have grown alongside China's healthcare reform. Through our robust technology platform and data-enabled operational capabilities, we connect patients, physicians, medical institutions, pharmaceutical companies, and payers within China's healthcare system, enabling them to deliver better medical and health services and more comprehensive financial protection for the Chinese people. As the population ages and the prevalence of chronic and critical illnesses continues to rise, China's healthcare expenditure has grown substantially and steadily.

Going forward, we will leverage our listing as an opportunity to continue empowering physicians, pharmaceutical companies, and insurers through technology and data, developing a symbiotic ecosystem; further strengthening our capabilities in serving physicians; enhancing our technology infrastructure and data insights; expanding our specialty pharmacy business through geographic expansion and investments in talent acquisition and retention; continuing to broaden the geographic coverage of our physician research assistance services and increasing service offerings; and driving transformation in China's healthcare industry by developing a network of health service providers and innovative insurance products that adapt to market changes — all while creating greater value for our shareholders and investors."

From left to right: Ma Xuguang, Chairman of the Board, Executive Director, and CEO of MedSci; Jing Liu, Managing Director of 5Y Capital; Li Ji, Executive Director and President of MedSci

5Y Capital's partnership with MedSci began in 2020. In our early conversations, the founders' professionalism, industry insight, and vision left a deep impression on us. Over eight years of entrepreneurship, MedSci has continuously broken new ground, building an ecosystem spanning medicine, pharmaceuticals, and health insurance, and providing infrastructure for China's pharmaceutical and healthcare professional services sectors. Even the pandemic in recent years failed to slow MedSci's rapid growth. We are fortunate to witness this new milestone for MedSci and look forward to seeing the company continue to forge ahead in this new chapter, creating even greater social value. Congratulations to MedSci!

Recently, Jing Liu, Managing Director of 5Y Capital, sat down with Ma Xuguang, Chairman of the Board, Executive Director, and CEO of MedSci. They discussed the pivotal decisions in MedSci's eight-year journey, the unique characteristics of the healthcare sector, and MedSci's mission. We have selected highlights from their conversation below; the full interview will be published next week — stay tuned.

"Empowering others to succeed is his ultimate goal."

Jing Liu: When I first met Lao Ma, MedSci was already a leading unicorn. I was actually quite nervous — I wasn't sure if he'd even respond to my WeChat message, so I came prepared and drafted a fairly long note.

Compared to many companies in similar spaces at that time, MedSci was genuinely distinctive. The company was remarkably low-key and grounded, advancing steadily step by step. That was what primarily motivated me to reach out. After meeting Lao Ma in person, I could clearly sense his deep sense of mission. He once said that empowering others to succeed is his ultimate goal, and I firmly believe in that.

Moreover, he had a sharp understanding of the relationships between the medical insurance system, physicians, and hospitals, as well as the fundamental pain points of the industry. We could see the founders' professionalism and their long-term vision for this endeavor. That was deeply compelling to 5Y Capital, which is why we moved through the process very quickly to close the financing.

Ma Xuguang: MedSci does operate according to certain principles, and these are tied to the natural rhythms of our industry. We focus on healthcare, and specifically on the B2B domain. Healthcare itself evolves very slowly, and B2B does too. We happen to be operating at the intersection of two of the slowest, most long-term-oriented fields, so you have to be particularly patient with this growth model — it demands both speed and stability.

At the same time, we thought about what kind of investors we should seek out. They should be people who truly understand our domain, who know what kind of company this field needs, and who are willing to support such a company. So when I first met you, I felt you really understood us — you knew what we were doing and what rhythm of development we needed to follow. I was very glad to ultimately gain 5Y Capital's support.

MedSci was founded in 2014. What was the original motivation for starting the company? Why choose to become an entrepreneur at that time?

Ma Xuguang: Previously, I worked at a multinational pharmaceutical company, rising from sales representative to district manager, regional manager, and eventually overseeing marketing for oncology and specialty drugs. Another part of my background is that I was once a practicing physician, so I had a somewhat different perspective on the pharmaceutical field.

As a medical representative, I might have seen only a drug. But over time, I realized that a drug is just one part of treatment; treatment is just one part of disease; disease is just one part of a person; and a person is just one part of society. With this in mind, when we think about treating someone, we also need to consider their ability to pay, their long-term employment situation, and so on — we need to look at the world through a wider lens.

I began to wonder whether I should step out of the pharmaceutical company and view drug marketing through a longer and broader perspective, and whether that could bring greater benefits to more people. So I left Bayer and started my own business.

How do you define success for your entrepreneurship, or for MedSci? And what about success in life?

Ma Xuguang: As MedSci has evolved, the standard of so-called success has kept changing. Today, our goal is clear: over the next ten years, we aim to serve 100 million medical and health insurance members, providing them with professional, high-standard, high-quality services, and managing a medical and health market of 300 billion RMB.

At MedSci's IPO on the 23rd, many of my brothers and sisters stood on stage with me. When I met them 20 or 15 years ago, they were very young, just in their twenties, doing frontline marketing work. Today, they may lead 2,000 people, manage hundreds of millions in business, and oversee pharmacies across the country. I think if there's anything that represents real success, this is it — and I hope they too will come to feel this way in the future.

We will publish the full interview of 5Y Talk x Ma Xuguang of MedSci next week — stay tuned.

Congratulations once again to MedSci!

5Y Capital seeks out, supports, and inspires founders who are willing to go it alone, providing them with support ranging from mentorship to all aspects of business operations. We believe that if the "crazy" you that others see begins to be believed in, the world will become a different place.

BEIJING · SHANGHAI · SHENZHEN · HONG KONG

WWW.5YCAP.COM